SCHEMBL4405261

SCHEMBL4405261

Cc1csc(-c2cc(C(=O)O)no2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.49
RARA P10276 2/20 0.47
RXRA P19793 2/20 0.47
RXRG P48443 1/20 0.47
PTPN1 P18031 2/20 0.46
DAO P14920 1/20 0.46
HPGD P15428 2/20 0.45
MAPT P10636 1/20 0.45
RECQL P46063 1/20 0.45
HTT P42858 2/20 0.43
KDM4E B2RXH2 1/20 0.41
RARG P13631 2/20 0.40
RARB P10826 1/20 0.40
CDH1 P12830 1/20 0.39
CTNNB1 P35222 1/20 0.39
TCF7L2 Q9NQB0 1/20 0.39
BRD4 O60885 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11902892 0.75 ALDH1A1 (0.54) ALDH1A1RARARXRARXRGPTPN1
SCHEMBL569698 0.73 ECE1 (0.56) ALDH1A1RARARXRARXRGPTPN1
SCHEMBL15190506 0.73 GRIN1 (0.36) DAOKDM4E
SCHEMBL892878 0.72 ALDH1A1 (0.72) ALDH1A1RARARXRAPTPN1HPGD
SCHEMBL619636 0.71 RAB9A (0.62) ALDH1A1PTPN1HPGDMAPTHTT
SCHEMBL21523599 0.71 ALDH1A1 (0.51) ALDH1A1RARARXRARXRGPTPN1
SCHEMBL23822894 0.70 RAB9A (0.41) ALDH1A1HPGDMAPTHTTKDM4E
SCHEMBL11092155 0.70 KDM4E (0.44) ALDH1A1DAOHPGDMAPTKDM4E
SCHEMBL1178549 0.69 PTPN1 (0.76) ALDH1A1RARARXRAPTPN1HPGD
SCHEMBL12198253 0.69 RARA (0.59) ALDH1A1RARARXRARXRGPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP claimed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US claimed
EP-1971600-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK Holdings Co., Ltd. (KR) 2008-09-24 EP claimed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO claimed
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
EP-1971600-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK Holdings Co., Ltd. (KR) 2008-09-24 EP disclosed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131336-A1 Isoxazole Derivatives and Use Thereof WNT3A, WNT1, WNT3 ALDH1A1 706/4885RARA 359/4885RXRA 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.